Please use this identifier to cite or link to this item:
Title: A novel form of glycolytic metabolism‐dependent cardioprotection revealed by PKCα and β inhibition
Authors: Brennan, S
Chen, S
Makwana, S
Martin, C
Sims, M
Alonazi, A
Willets, J
Squire, I
Rainbow, R
First Published: 26-Jun-2019
Publisher: Wiley, Physiological Society
Citation: The Journal of Physiology, 2019
Abstract: Background Hyperglycaemia has a powerful association with adverse prognosis for patients with acute coronary syndromes (ACS). Previous work shows high glucose prevents ischaemic preconditioning and causes electrical and mechanical disruption via PKCα/β activation. The aims of this study were to: 1) determine whether the adverse clinical association of hyperglycaemia in ACS can be replicated in preclinical cellular models of ACS. 2) Ascertain the importance of PKCα/β activation to the deleterious effect of glucose. Methods Freshly isolated rat, guinea pig or rabbit cardiomyocytes were exposed to simulated ischaemia after incubation in the presence of normal (5 mm) or high (20 mm) glucose in the absence or presence of small molecule or tat‐peptide‐linked PKCαβ inhibitors. In each of the 4 conditions, the following hallmarks of cardioprotection were recorded using electrophysiology or fluorescent imaging: cardiomyocyte contraction & survival, action potential stability & time to failure, intracellular calcium & ATP, mitochondrial depolarisation, ischaemia‐sensitive leak current and time to Kir6.2 opening. Results High glucose alone resulted in decreased cardiomyocyte contraction and survival, however, imparted cardioprotection in the presence of PKCα/β inhibitors. This cardioprotective phenotype displayed improvements in all measured parameters and decreased myocardium damage during whole heart coronary ligation experiments. Conclusions High glucose is deleterious to cellular and whole‐heart models of simulated ischaemia, in keeping with the clinical association of hyperglycaemia with adverse outcome in ACS. PKCαβ inhibition revealed high glucose to show a cardioprotective phenotype in this setting. This study suggests the potential for therapeutic application of PKCαβ inhibition in ACS associated with hyperglycaemia.
DOI Link: 10.1113/JP278332
ISSN: 0022-3751
Embargo on file until: 26-Jun-2020
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2019, Wiley, Physiological Society. Deposited with reference to the publisher’s open access archiving policy. (
Description: The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Molecular and Cell Biology

Files in This Item:
File Description SizeFormat 
Brennan_et_al-2019-The_Journal_of_Physiology.pdfPost-review (final submitted author manuscript)2.15 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.